EARLY SALVAGE TREATMENT WITH SECOND-GENERATION NOVEL AGENTS AT BIOCHEMICAL RELAPSE PROLONGS OVERALL SURVIVAL: A REAL-WORLD SINGLE CENTER EXPERIENCE
Author(s): ,
Alessandra Romano
Affiliations:
CHIRMED- Dipartimento Chirurgia generale e specialità medico-chirurgiche-Hematology Section,Università degli Studi di Catania,Catania,Italy
,
Vittorio Del Fabro
Affiliations:
Divisione di Ematologia,AOU Policlinico Vittorio Emanuele di Catania,Catania,Italy
,
Valerio Leotta
Affiliations:
Divisione di Ematologia,AOU Policlinico Vittorio Emanuele di Catania,Catania,Italy
,
Uros Markovic
Affiliations:
Divisione di Ematologia,AOU Policlinico Vittorio Emanuele di Catania,Catania,Italy
,
Enrica Martino
Affiliations:
Divisione di Ematologia,AOU Policlinico Vittorio Emanuele di Catania,Catania,Italy
,
Marina Parisi
Affiliations:
Divisione di Ematologia,AOU Policlinico Vittorio Emanuele di Catania,Catania,Italy
,
Valeria Calafiore
Affiliations:
Divisione di Ematologia,AOU Policlinico Vittorio Emanuele di Catania,Catania,Italy
,
Giuseppe Sapienza
Affiliations:
Divisione di Ematologia,AOU Policlinico Vittorio Emanuele di Catania,Catania,Italy
,
Alessandra Orofino
Affiliations:
CHIRMED- Dipartimento Chirurgia generale e specialità medico-chirurgiche-Hematology Section,Università degli Studi di Catania,Catania,Italy
,
Francesco Di Raimondo
Affiliations:
CHIRMED- Dipartimento Chirurgia generale e specialità medico-chirurgiche-Hematology Section,Università degli Studi di Catania,Catania,Italy;Divisione di Ematologia,AOU Policlinico Vittorio Emanuele di Catania,Catania,Italy
Concetta Conticello
Affiliations:
Divisione di Ematologia,AOU Policlinico Vittorio Emanuele di Catania,Catania,Italy
EHA Library. Di Raimondo F. Jun 14, 2019; 266431; PF632
Francesco Di Raimondo
Francesco Di Raimondo
Contributions
Abstract

Abstract: PF632

Type: Poster Presentation

Presentation during EHA24: On Friday, June 14, 2019 from 17:30 - 19:00

Location: Poster area

Background

Despite therapeutic advances, multiple myeloma (MM) remains largely incurable and patients invariable develop relapsed or refractory (R/R) disease. Relapse can be characterized according to disease aggressiveness and the presence of clinical symptoms. Aggressive relapse can occur at biochemical level, due to rapid and relevant increase of monoclonal component or LDH, or at clinical level, defined by the presence of extramedullary disease, acute renal injury or progression to secondary plasma cell leukemia. 

Aims

To identify the clinical outcome upon treatment with second generation novel agents (pomalidomide, carfilzomib) and monoclonal antibodies (elotuzumab, daratumumab), we collected evidence of the best timing in providing early salvage treatment to RRMM.

Methods
According to regulatory Italian laws, patients (N=128) received one of the following regimens: KRd (N=42, group A), Poma-Dex (N=77, group B), Daratumumab (in monotherapy, N=12; associated to bortezomib, N=18, associated to lenalidomide, N=3), or Elotuzumab associated to lenalidomide (N=12, group C). Among second generation novel agents-treated patients (N=128), 100 patients were exposed only to pomalidomide (N=57), Daratumumab (N=4), Daratumumab plus bortezomib and desamethasone (N=6), Daratumumab plus lenalidomide and desamethasone (N=1), Elotuzumab plus lenalidomide and desamethasone (N=8), Carfilzomib plus lenalidomide and desamethasone (N=24); 20 patients were exposed to two second generation of novel agents (pomalidomide and KRd N=4, pomalidomide and Daratumumab N=4, pomalidomide and EloRd N=2, pomalidomide and DaratumumabVD N=3, KRd and Daratumumab N=1, KRd and DaratumumabVD N=5, EloRd and DaratumumabVD N=1), 7 patients to three combination (pomalidomide and KRd and Daratumumab N=4, pomalidomide and KRd and Daratumumab VD N=2,  KRd and Dararumumab and DratumumabVD N=1), 1 patient to pomalidomide, daratumumab, EloRd and KRd. 

Results

From July 2014 to January 2019 we evaluated 166 R/R MM treatments of 128 patients (58% males, median age 62 years, range 45-78), relapsed (N=76, 59%) and relapsed/refractory (N=52, 41%) patients, treated at biochemical (N=87, 68%) or clinical relapse (N=41, 32%). Median number of previous lines was 3 (1-13), including autologous stem cell transplantation (ASCT) in half of cases (N=64, 50%). FISH was repeated before to start the second-generation drugs, and it was available in 53 cases: 11 carried on high-risk (del 17p, t4;14 or t14;16) and 42 standard-risk cytogenetics, without any additional marker compared to the matched sample at diagnosis.

For the whole cohort, longer overall survival (OS) was associated to treatment at biochemical relapse (27.8 vs 15.2 months, p=0.0005), in relapsed patients instead of relapsed and refractory (34.1 vs 19.3 months, p=0.0004), who received less than 3 lines of therapy (33.6 vs 19.1 months, p=0.002), carrying standard-risk cytogenetics (20.4 vs 11.2 months, p-value not significant for low numbers in two groups) without any significant difference due to previous ASCT or the type of second-generation treatment chosen. In multivariable analysis only type of relapse (biochemical versus clinical) and refractory status were independent predictors of overall survival (p<0.0001).

Conclusion
In our community setting data, heavily pretreated patients achieved improvement of outcome obtaining a median OS >12 months, using second generation novel agents. Earlier treatment at biochemical asymptomatic relapse is associated with longer OS, suggesting that the most efficacious combinations should be anticipated within the first lines to prolong OS. 

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Monoclonal antibody, Multiple myeloma, Refractory, Survival

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies